Aigen Investment Management LP Has $321,000 Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Aigen Investment Management LP grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 40.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,332 shares of the biotechnology company’s stock after buying an additional 666 shares during the quarter. Aigen Investment Management LP’s holdings in Ascendis Pharma A/S were worth $321,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $30,000. Jones Financial Companies Lllp increased its stake in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares in the last quarter. Groupama Asset Managment acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $60,000. Finally, GAMMA Investing LLC increased its stake in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares in the last quarter.

Ascendis Pharma A/S Trading Down 3.8 %

Shares of ASND opened at $145.74 on Friday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $158.00. The stock has a market cap of $8.84 billion, a P/E ratio of -20.53 and a beta of 0.62. The stock’s 50-day moving average price is $137.32 and its two-hundred day moving average price is $134.39.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Wall Street Analyst Weigh In

ASND has been the subject of a number of research reports. Oppenheimer lowered their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Cantor Fitzgerald lifted their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. Finally, Evercore ISI lifted their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.